Pizzo PA, Robichaud KJ, Gill FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med72:101-111, 1982
2.
Lyman CA, Walsh TJ: Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs44:9-35, 1992
3.
Kinsky SC: Antibiotic interactions with model membranes. Ann Rev Pharmacol10:119-142, 1970
4.
Medoff G., Kobayashi GS: Strategies in the treatment of systemic fungal infections. N Engl J Med302:145-155, 1980
5.
Wilson E., Thorson L., Speert DP: Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother35:796-800, 1991
Atkinson AJ, Bennett JE: Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother13:271-276, 1978
8.
Craven PC, Ludden TM, Drutz DJ, et al: Excretion pathways of amphotericin B. J Infect Dis140:329-341, 1979
9.
Gondal JA, Swartz RP, Rahman A.: Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother33:1544-1548, 1989
10.
Janknegt R. , de Marie S., Bakker-Woudenberg IA, et al: Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet23:279-291, 1992
11.
Fungizone Intravenous, package insert (revised Sept 1993). ER Squibb & Sons Inc, Princeton, NJ
12.
Heidemann H. , Gerkens JF, Spickard WA, et al: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med75:476-481, 1983
Patterson TF , Andriole VT: The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol25:63-68, 1989 (supp)
